Laura Bhatt

Laura Bhatt has contributed to understanding mechanisms of acquired resistance to CDK4/6 inhibitors in breast cancer from a pharmaceutical research perspective. Her work characterized Rb1 loss, CDK2 upregulation, and cyclin E amplification as key drivers of resistance to palbociclib and abemaciclib. She has investigated combination approaches pairing next-generation CDK inhibitors or PI3K inhibitors with endocrine therapy to overcome CDK4/6 resistance. Her research directly informs ongoing clinical trial design for post-CDK4/6 inhibitor treatment strategies.